Alcon acquires Neurotech for USD 550 million. Needham targets Alcon stock at USD 98

Published on 10/26/2026 at 09:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal may lift sales growth but dilute core earnings per share in 2027. Alcon stock stands at EUR 63.07 on October 26, 2026, 0.65 percent above Xetra close.

Acquisition broadens retinal reach

Alcon paid USD 550 million for Neurotech Pharmaceuticals on October 20, 2026.
Needham reiterated a USD 98.00 target for Alcon on October 21, 2026.
Alcon stock trades at EUR 63.07 at 9:34 a.m. CET at Lang & Schwarz on October 26, 2026, 0.65 percent above the Xetra close of October 23, 2026.
Alcon is scheduled to report third-quarter results on November 10, 2026.

Watercolor illustration of a stylized human eye centered in wide panoramic composition. Iris rendered in intricate pastel rainbow patterns in lavender, mint, peach, gold with delicate ink linework and translucent watercolor washes — Alcon CH0432492467: Aquarell Illustration eines Auges mit bunten Iris Mustern in zarten Pastellfarben, Illustration mit AI erstellt.

Alcon Inc. (ISIN CH0432492467) paid USD 550 million for Neurotech Pharmaceuticals on October 20, 2026, expanding its retinal disease portfolio with ENCELTO. The acquisition gives Alcon a commercial position in the first FDA-approved treatment for adults with MacTel, according to FinanzNachrichten.

Neurotech adds a retinal therapy

The transaction broadens Alcon's Surgical portfolio beyond devices and implants. The company said the deal should be modestly accretive to net sales growth but slightly dilutive to core diluted earnings per share in 2027, with accretion expected afterward, as reported by MarketScreener.

ENCELTO is intended for surgical implantation and addresses MacTel, a rare progressive retinal disease. Alcon said the product is currently available in the United States, while the acquisition also brings Neurotech's encapsulated cell therapy platform into the eye-care group's pipeline.

What does the target signal?

Needham analyst David Saxon reiterated a Buy rating and set a USD 98.00 price target on October 21, 2026, according to Markets Insider. The target frames Neurotech as a growth contributor, although Alcon's own transaction outlook includes the 2027 earnings dilution.

Three recent milestones

On October 20, 2026, Alcon announced the USD 550 million Neurotech acquisition. On October 21, 2026, Needham reiterated its USD 98.00 target. On October 22, 2026, the same analyst view was reported again with the USD 98.00 target, according to Markets Insider.

When are results due?

Alcon is scheduled to release third-quarter 2026 results on November 10, 2026, according to MarketScreener. That report will provide the next quantified test of whether surgical demand and the Neurotech strategy can support growth while absorbing the transaction's initial earnings effect.

Stock moves above the Xetra close

Alcon stock was trading at EUR 63.07 at Lang & Schwarz on October 26, 2026 at 9:34 a.m. CET, 0.65 percent above the Xetra close of October 23, 2026 at EUR 62.66. The quote was in the pre-market phase for Xetra.

The further course of trading is shown by the continuously updated real-time quote of Alcon stock.